Unknown PHASE2 INTERVENTIONAL 1-arm NCT04414969

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Anti-PD-1 Antibody, Peg-Asparaginase, Chidamide Combined With Radiotherapy for the First-line Treatment of Patients With Stage I/II Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL): An Open-label, Multicenter, Phase II Trial

Sponsor: Hunan Cancer Hospital

Conditions Chemotherapy Effect Epigenetic Disorder Immune Checkpoint Inhibitor NK/T-cell Lymphoma of Nasal Cavity

Interventions Anti-PD-1 antibody+Peg-Asparaginase+Chidamide

Updated 6 times since 2020 Last updated: Jul 2, 2020 Started: Jun 26, 2020 Primary completion: Jul 1, 2022 Completion: Jul 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chemotherapy Effect and Epigenetic Disorder, this trial is ongoing. The trial is conducted by Hunan Cancer Hospital and has accumulated 6 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Aug 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Aug 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jan 2021 — Jul 2024 [monthly]

Recruiting PHASE2
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Jul 2020 — Aug 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hunan Cancer Hospital

Data source: Hunan Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China